In contrast, RRM1, RRM2, and RRM2B were ranked in the top 10% of the down-regulated DEGs in only 8.4% (30 of 358), 4.5% (16 of 355), and 4.8% (10 of 209) of the cancer studies, respectively. Here, RRM2B is linked to cancer.